BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
67.94
+1.55 (2.33%)
At close: Oct 19, 2026, 4:00 PM EDT
68.24
+0.30 (0.44%)
Pre-market: Oct 20, 2026, 7:01 AM EDT
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $13.28 billion as of October 19, 2026. It is the 1,696th most valuable company in the world and the 618th biggest in the United States. Its market cap has increased by 26.51% in one year.
Market Cap
13.28B
Enterprise Value
15.93B
1-Year Change
26.51%
Global Rank
Country Rank
#618 United States
Category
ChartMarket Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $13.28B, an increase of 300.08%. That is a compound annual growth rate of 20.86%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 19, 2026 | 13.28B | -9.89% |
| Dec 31, 2025 | 14.74B | 184.24% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Exelixis | 15.42B |
| Ascendis Pharma | 14.79B |
| Halozyme Therapeutics | 13.83B |
| Jazz Pharmaceuticals | 13.65B |
| Corcept Therapeutics | 11.91B |
| Summit Therapeutics | 11.70B |
| Bio-Techne | 11.38B |
| BioMarin Pharmaceutical | 10.58B |